Related Experiment Video
Updated: Apr 22, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Clinical integration of next generation sequencing: coverage and reimbursement challenges
Patricia A Deverka1, Jennifer C Dreyfus
1Adjunct Associate Professor at the University of North Carolina at Chapel Hill School of Pharmacy where she focuses on issues related to personalized medicine, comparative effectiveness research, evidence standards and stakeholder engagement.
Abstract:
Public and private payers face complex decisions regarding whether, when, and how to cover and reimburse for next generation sequencing (NGS)-based tests. Yet a predictable reimbursement pathway is critical both for patient access and incentives to provide the market with better clinical evidence. While preliminary data suggests that payers will use similar evidentiary standards as those used to evaluate established molecular diagnostic tests, the volume and complexity of information generated by NGS raises a host of additional considerations for payers that are specific to this technology.
More Related Videos
Related Concept Videos
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
Sanger Sequencing
RNA-seq
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Genomics
Maxam-Gilbert Sequencing
Challenges of the Maxam-Gilbert Method
The...

